{"nct_id":"NCT04934722","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","status_verified_date":"2025-09","start_date":"2021-05-25","start_date_type":"ACTUAL","primary_completion_date":"2022-10-31","primary_completion_date_type":"ACTUAL","completion_date":"2025-09-10","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}